Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma
1 other identifier
observational
200
1 country
1
Brief Summary
Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2019
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 3, 2019
CompletedFirst Submitted
Initial submission to the registry
February 3, 2020
CompletedFirst Posted
Study publicly available on registry
February 11, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2025
CompletedApril 23, 2025
April 1, 2025
6.5 years
February 3, 2020
April 18, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Incidence of driver gene abnormalities
the incidence of driver gene abnormalities by fixed gene testing technology
from the day of the first patient was included to the date of the end of this trial, assessed up to 36 months
Secondary Outcomes (3)
objective response rate
from the date of the first patient was included to the date of the end of this trial, assessed up to 36 months
5-year overall survival
from the date of the first patient was included to the date of the end of this trial, assessed up to 5 years
Clinicopathological Characteristics
from the date of the first patient was included to the date of the end of this trial, assessed up to 36 months
Eligibility Criteria
Including demographic characteristics / clinical characteristics / pathological characteristics / treatment and efficacy evaluations.
You may qualify if:
- Diagnosed as lymphoma (according to WHO 2017 classification criteria)
- Life expectancy no less than 3 months
- Agreeing to sign the written informed consents
You may not qualify if:
- Other malignant tumor history or active malignant tumor need be treated
- Researchers determine unsuited to participate in this trial
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university
Zhengzhou, Henan, China
Biospecimen
Tumor tissue specimen
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Yanyan Liu, M.D. Ph.D
Henan Cancer Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director
Study Record Dates
First Submitted
February 3, 2020
First Posted
February 11, 2020
Study Start
January 3, 2019
Primary Completion
June 30, 2025
Study Completion
December 31, 2025
Last Updated
April 23, 2025
Record last verified: 2025-04
Data Sharing
- IPD Sharing
- Will not share